Validation of novel biomarkers for treatment response to rush oral immunotherapy for food allergy in children

Validation of novel biomarkers for treatment response to rush oral immunotherapy for food allergy in children - Immunoglobulin Maturation and Affinity Kinetics in Immunotherapy for Food Allergy (IMAKIFA) Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029742

Enrollment

Registered

2017-10-28

Start date

2017-10-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food allergy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with food allergy who undergo rush oral immunotherapy

Exclusion criteria

Exclusion criteria: 1.patients with any chronic disease other than allergic diseases 2.patients with uncontrolled asthma or atopic dermatitis

Design outcomes

Primary

Measure	Time frame
Association of serum levels of allergen-specific IgE, IgG1, IgG2, IgG3, IgG4 and IgA(measured by highly sensitive DLC/DCP chip assay), antigen affinity of IgE and IgG1 (by competition binding assay using DLC/DCP chip) and desensitization levels (tolerable amount of food) induced by oral immunotherapy	—

Secondary

Measure	Time frame
Association of other immonological markers (basophil activation, urinary prostaglandin etc) and desensitization levels (tolerable amount of food) induced by oral immunotherapy	—

Countries

Japan

Contacts

Public ContactRyo Imakiire

Mie National Hospital Department of Pediatrics

iamluckymanjp@yahoo.co.jp059-232-2531

Outcome results